JP2024538141A - 活性化可能なポリペプチド複合体 - Google Patents
活性化可能なポリペプチド複合体 Download PDFInfo
- Publication number
- JP2024538141A JP2024538141A JP2024522609A JP2024522609A JP2024538141A JP 2024538141 A JP2024538141 A JP 2024538141A JP 2024522609 A JP2024522609 A JP 2024522609A JP 2024522609 A JP2024522609 A JP 2024522609A JP 2024538141 A JP2024538141 A JP 2024538141A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- activatable
- domain
- seq
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256417P | 2021-10-15 | 2021-10-15 | |
| US63/256,417 | 2021-10-15 | ||
| US202263370897P | 2022-08-09 | 2022-08-09 | |
| US63/370,897 | 2022-08-09 | ||
| PCT/US2022/078160 WO2023064929A1 (en) | 2021-10-15 | 2022-10-14 | Activatable polypeptide complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024538141A true JP2024538141A (ja) | 2024-10-18 |
| JP2024538141A5 JP2024538141A5 (cg-RX-API-DMAC7.html) | 2025-10-21 |
Family
ID=84330396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522609A Pending JP2024538141A (ja) | 2021-10-15 | 2022-10-14 | 活性化可能なポリペプチド複合体 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230174995A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4416178A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024538141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240118749A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022367525A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3235018A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024001178A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312143A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024004564A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202323282A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023064929A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025199278A2 (en) * | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| WO2025235515A1 (en) | 2024-05-07 | 2025-11-13 | Cytomx Therapeutics, Inc. | Activatable polypeptide complex formulations |
| WO2025240659A2 (en) * | 2024-05-14 | 2025-11-20 | Cytomx Therapeutics, Inc. | Activatable constructs, compositions and methods |
| WO2026024841A1 (en) | 2024-07-24 | 2026-01-29 | Astellas Us Llc | Bispecific antibodies that bind cd3 and muc1 and methods of use thereof |
| WO2026067689A1 (zh) * | 2024-09-28 | 2026-04-02 | 浙江道尔生物科技有限公司 | 肿瘤特异性激活的蛋白药物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US6174666B1 (en) | 1992-03-27 | 2001-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Method of eliminating inhibitory/instability regions from mRNA |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
| IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
| AU1456101A (en) | 1999-11-03 | 2001-05-14 | Maxygen, Inc. | Antibody diversity generation |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| PE20150605A1 (es) | 2012-04-27 | 2015-05-28 | Cytomx Therapeutics Inc | Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico |
| SG11201408554QA (en) | 2012-06-22 | 2015-02-27 | Cytomx Therapeutics Inc | Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof |
| EP2882844B1 (en) | 2012-08-10 | 2018-10-03 | Cytomx Therapeutics Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
| US9487590B2 (en) | 2012-09-25 | 2016-11-08 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind interleukin-6 receptor and methods of use thereof |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| US9540440B2 (en) | 2013-10-30 | 2017-01-10 | Cytomx Therapeutics, Inc. | Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| BR112017023872A2 (pt) | 2015-05-04 | 2018-07-24 | Cytomx Therapeutics Inc | anticorpos anti-cd166, anticorpos anti-cd166 ativáveis e métodos de uso dos mesmos |
| AU2016258988A1 (en) | 2015-05-04 | 2017-12-07 | Cytomx Therapeutics, Inc | Anti-ITGa3 antibodies, activatable anti-ITGa3 antibodies, and methods of use thereof |
| TWI787796B (zh) | 2015-05-04 | 2022-12-21 | 美商Cytomx生物製藥公司 | 抗cd71抗體類、可活化之抗cd71抗體類及使用彼等之方法 |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| WO2017162587A1 (en) * | 2016-03-22 | 2017-09-28 | F. Hoffmann-La Roche Ag | Protease-activated t cell bispecific molecules |
| CA3032430A1 (en) * | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN111247171A (zh) | 2017-10-14 | 2020-06-05 | 西托姆克斯治疗公司 | 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法 |
| WO2019077092A1 (en) * | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES |
| US20210324088A1 (en) | 2018-05-02 | 2021-10-21 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| JP7729778B2 (ja) * | 2019-03-28 | 2025-08-26 | オリオニス バイオサイエンシズ,インコーポレイテッド | Fms様チロシンキナーゼ3(flt3)に対するキメラタンパク質およびキメラタンパク質複合体 |
-
2022
- 2022-10-14 US US18/046,860 patent/US20230174995A1/en active Pending
- 2022-10-14 CA CA3235018A patent/CA3235018A1/en active Pending
- 2022-10-14 EP EP22801672.1A patent/EP4416178A1/en active Pending
- 2022-10-14 TW TW111139144A patent/TW202323282A/zh unknown
- 2022-10-14 KR KR1020247013820A patent/KR20240118749A/ko active Pending
- 2022-10-14 MX MX2024004564A patent/MX2024004564A/es unknown
- 2022-10-14 JP JP2024522609A patent/JP2024538141A/ja active Pending
- 2022-10-14 AU AU2022367525A patent/AU2022367525A1/en active Pending
- 2022-10-14 IL IL312143A patent/IL312143A/en unknown
- 2022-10-14 WO PCT/US2022/078160 patent/WO2023064929A1/en not_active Ceased
-
2024
- 2024-04-15 CL CL2024001178A patent/CL2024001178A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3235018A1 (en) | 2023-04-20 |
| CL2024001178A1 (es) | 2024-10-04 |
| IL312143A (en) | 2024-06-01 |
| MX2024004564A (es) | 2024-04-30 |
| US20230174995A1 (en) | 2023-06-08 |
| AU2022367525A1 (en) | 2024-05-02 |
| TW202323282A (zh) | 2023-06-16 |
| EP4416178A1 (en) | 2024-08-21 |
| WO2023064929A1 (en) | 2023-04-20 |
| KR20240118749A (ko) | 2024-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7646361B2 (ja) | 抗pvrig/抗tigit二重特異性抗体および使用方法 | |
| US11780919B2 (en) | Bispecific antigen binding molecules targeting OX40 and FAP | |
| JP2023160982A (ja) | Tigitに対する単一ドメイン抗体及びその変異体 | |
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 cd38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| US9540442B2 (en) | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece | |
| US20220010010A1 (en) | Antibodies specific for immunoglobulin-like transcript 3 (ilt3) and uses thereof | |
| US20230174995A1 (en) | Activatable polypeptide complex | |
| JP7754506B2 (ja) | ポリオウイルス受容体(pvr)に対する抗体およびその使用 | |
| TWI917387B (zh) | 抗cd93之構築體及其用途 | |
| KR20180130574A (ko) | 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법 | |
| CA3100829A1 (en) | Antibodies specific for gucy2c and uses thereof | |
| US20230183382A1 (en) | Activatable polypeptide complex | |
| KR20240032847A (ko) | Cldn18.2 및 cd3에 결합하는 이중특이 결합제 | |
| WO2021129775A1 (zh) | 抗ctla-4单克隆抗体及其制备方法与应用 | |
| WO2023064955A1 (en) | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex | |
| JP2025531805A (ja) | 新規のpd1標的化il-15免疫サイトカインおよびvitokine融合物 | |
| WO2025184154A1 (en) | Pd1-targeted novel il-2 vitokine fusions | |
| US20250243283A1 (en) | Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex | |
| TW202346366A (zh) | 標靶pd-l1和cd40的抗原結合蛋白及其製備和應用 | |
| JP2025509555A (ja) | Epcamおよび/またはcd137に結合する結合剤 | |
| CN118103406A (zh) | 可激活多肽复合物 | |
| WO2025235515A1 (en) | Activatable polypeptide complex formulations | |
| TW202434631A (zh) | 抗il-2抗體之使用方法 | |
| WO2024044675A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies | |
| JP2025510566A (ja) | 抗グルココルチコイド誘導性tnfr関連(gitr)タンパク質抗体及びその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251010 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251010 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260804 |